An FDA-approved drug initially used to treat insulin resistance in diabetics has shown promise as a way to improve cognitive performance in some people with Alzheimer’s disease. Working with genetically engineered mice designed to serve as models for Alzheimer’s, UTMB researchers found that treatment with the anti-insulin-resistance drug rosiglitazone enhanced learning and memory as well as normalized insulin resistance. “Using this drug appears to restore the neuronal signaling required for proper cognitive function,” said UTMB professor Larry Denner, the lead author of a paper describing this work now online in the Journal of Neuroscience. The news also appears in the Times of India, Diabetes News and Yahoo! News.